Choice of anti-angiogenic agents in second-line treatment in patients with metastatic colon cancer: bevacizumab, aflibercept, ramucirumab (a literature review)
Over the last decade, the possibility of the drug therapy for patients with metastatic colon cancer (mCC) has increased due to the targeted drugs, because most of those drugs have had antiangiogenic activity (bevacizumab, aflibercept, ramucirumab, regorafenib). The combination of chemotherapy and be...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2015-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/27035 |